報價延遲最少15分鐘:2025/09/17 06:07 EDT
盤前時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
35.96
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.77/-0.25
|
|
企業價值
1.79B
|
| 資產負債 |
|
每股賬面淨值
9.35
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
465.31M
|
|
每股收益
7.66
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/17 06:07 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct salesforce and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. |
